Entera Bio to Participate in Upcoming Investor and Scientific Conferences

Core Insights - Entera Bio Ltd. is focused on developing orally delivered peptides and small therapeutic proteins to address significant unmet medical needs in the healthcare sector [2] Group 1: Company Overview - Entera is a clinical stage company with a proprietary technology platform (N-Tab™) aimed at transforming the standard of care through oral peptide or protein replacement therapies [2] - The company has five differentiated, first-in-class oral peptide programs expected to enter clinical trials (Phase 1 to Phase 3) by 2025 [2] - The most advanced product candidate, EB613, is being developed as the first oral, osteoanabolic once-daily tablet treatment for post-menopausal women with low bone mineral density (BMD) and high-risk osteoporosis [2] Group 2: Clinical Development - A Phase 2 study of EB613 tablets (n=161) met both primary (PD/bone turnover biomarker) and secondary endpoints (BMD) [2] - Entera is preparing to initiate a Phase 3 registrational study for EB613, with FDA qualification of a quantitative BMD endpoint expected by January 2025 [2] - The EB612 program is being developed as the first oral PTH(1-34) tablet peptide replacement therapy for hypoparathyroidism [2] Group 3: Additional Product Development - Entera is also developing the first oral oxyntomodulin, a dual-targeted GLP1/glucagon peptide, in tablet form for obesity treatment [2] - The first oral GLP-2 peptide tablet is being developed as an injection-free alternative for patients with rare malabsorption conditions, in collaboration with OPKO Health [2] Group 4: Upcoming Conferences - Management will participate in several upcoming investor and scientific conferences, including: - H.C. Wainwright 26th Annual Global Investment Conference on September 9, 2024 [1] - American Society for Bone and Mineral Research 2024 Annual Meeting on September 28, 2024 [1] - 7th Annual Evercore ISI HealthCONx Conference on December 4, 2024 [1]